Deuterated compounds useful for treating neurodegenerative diseases

Abstract

The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds.

1 - 45 . (canceled) 
     
     
         46 . A compound of Formula I, II, IIIA, IIIB, or IV,
 wherein Formula I has the structure:   
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, wherein:
 each of R 1 , R 1′ , R 2 , R 2′ , R 3 , and R 4  is independently hydrogen, deuterium, optionally substituted alkyl, or optionally substituted deuterated-alkyl; or R 2  and R 2′  taken together form ═O, ═S, ═CH 2 , ═CHD, or ═CD 2 ; 
 R 4′  is hydrogen or deuterium; 
 R 5  is heterocycloalkyl or deuterated-heterocycloalkyl; 
 X is CH 2 , CDH, CD 2 , NH, O or S; 
 n is 0, 1, 2, 3, 4, or 5; and 
 m is 1 or 2; 
 with the proviso that the compound of Formula I comprises at least one carbon-bound deuterium; 
 
         wherein Formula II has the structure: 
       
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, wherein:
 p is 0, 1, 2, 3, 4, 5, or 6; 
 A 1  is hydrogen or deuterium; 
 each of Y, V, and W is independently CH 2 , CDH, CD 2 , NH, O, or S; 
 each of R 10  and R 11  is independently hydrogen, deuterium, optionally substituted alkyl, or optionally substituted deuterated-alkyl; 
 each of R 12  and R 13  is independently hydrogen, —NR a R b , —OH, —C(═O)OR a , —C(═O)NHR a , —NHC(═O)R a , —NHS(═O) 2 R a , optionally substituted alkyl, or optionally substituted deuterated-alkyl; 
 each of R a  and R b  is independently hydrogen, optionally substituted alkyl, or optionally substituted deuterated-alkyl; and 
 Z is an optionally substituted heterocycloalkyl, an optionally substituted deuterated-heterocycloalkyl, an optionally substituted heteroaryl, an optionally substituted deuterated-heteroaryl, or 
 
       
       
         
           
           
               
               
           
         
         
           L 1  is a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted deuterated-alkylene, optionally substituted cycloalkylene, optionally substituted deuterated-cycloalkylene, optionally substituted alkenylene, optionally substituted deuterated-alkenylene, optionally substituted arylene, optionally substituted deuterated-arylene, optionally substituted cycloalkenylene, and optionally substituted deuterated-cycloalkenylene; 
           E is selected from the group consisting of: 
         
       
       
         
           
           
               
               
           
         
         
            pyrrolidinyl, and deuterated-pyrrolidinyl; 
           each of E 1 , E 2 , E 4 , E 5 , and E 6  independently is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted deuterated-alkyl, optionally substituted cycloalkyl, optionally substituted deuterated-cycloalkyl, optionally substituted aryl, optionally substituted deuterated-aryl, optionally substituted arylalkyl, and optionally substituted deuterated-arylalkyl; 
           each E 3  is independently selected from the group consisting of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted deuterated-alkyl, optionally substituted aryl, optionally substituted deuterated-aryl, acyloxyl, alkoxyl, and deuterated-alkoxyl; 
           with the proviso that the compound of Formula II comprises at least one carbon-bound deuterium; 
         
         wherein Formula IIIA has the structure: 
       
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, wherein:
 X is CH 2 , CDH, CD 2 , NH, O or S; 
 each of A 1 , A 2 , A 3 , and A 4  is independently hydrogen or deuterium; 
 s is 0, 1, 2, 3 or 4; 
 each of R 19 , R 19′ , R 20 , R 20′ , R 21 , R 21′ , R 22 , R 22′  and R 24  is independently hydrogen, deuterium, optionally substituted alkyl, or optionally substituted deuterated-alkyl; or 
 R 20  and R 20′  taken together form ═O, ═S, ═CH 2 , ═CDH, or ═CD 2 ; or 
 R 20  and R 21  taken together with the atoms to which they are attached form an optionally substituted cycloalkyl or optionally substituted deuterated-cycloalkyl; or R 20  and R 21  taken together with the atoms to which they are attached form an optionally substituted aryl or optionally substituted deuterated-aryl; or 
 R 19  and R 20  taken together with the atoms to which they are attached form an optionally substituted cycloalkyl or optionally substituted deuterated-cycloalkyl; or R 19  and R 20  taken together with the atoms to which they are attached form an optionally substituted aryl or optionally substituted deuterated-aryl; and 
 R 23  is optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted aryl or optionally substituted deuterated-aryl; or R 22  and R 23  taken together with the atoms to which they are attached form an optionally substituted heterocycloalkyl or optionally substituted deuterated-heterocycloalkyl; 
 with the proviso that the compound of Formula IIIA comprises at least one carbon-bound deuterium; 
 
         wherein Formula IIIB has the structure: 
       
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, wherein:
 X is CH 2 , CDH, CD 2 , NH, O or S; 
 each of A 1 , A 2 , A 3 , A 4 , and R 25a  is independently hydrogen or deuterium; 
 s is an integer from 1 to 8; 
 each of R 19 , R 19′ , R 26 , and R 27  is independently hydrogen, deuterium, optionally substituted alkyl, or optionally substituted deuterated-alkyl; 
 R 24  is hydrogen, optionally substituted alkyl, or optionally substituted deuterated-alkyl; 
 R 25b  is hydrogen, deuterium, halo, hydroxyl, alkoxy, deuterated-alkoxy, optionally substituted alkyl, optionally substituted deuterated-alkyl, optionally substituted cycloalkyl, optionally substituted deuterated-cycloalkyl, optionally substituted aryl, or optionally substituted deuterated-aryl; 
 with the proviso that the compound of Formula IIIB comprises at least one carbon-bound deuterium; and 
 
         wherein Formula IV has the structure: 
       
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, wherein:
 p is 1, 2, 3, 4, 5, or 6; 
 each of Y, V, and W is independently CH 2 , CDH, CD 2 , NH, O or S; 
 A 1  is hydrogen or deuterium; 
 each of R 30 , R 31 , R 32 , R 32′  R 33 , R 34 , R 34′ , R 35 , R 35′ , R 36 , and R 36′  is independently hydrogen, deuterium, optionally substituted alkyl, or optionally substituted deuterium-alkyl; or 
 R 34  and R 36  taken together with the atoms to which they are attached form an optionally substituted carbocyclic ring or optionally substituted deuterated-carbocyclic ring; 
 E is —CHR c R d , —CDR c R d , —NR c R d , —OR c , or —SR c ; and 
 each of R c  and R d  is independently hydrogen, deuterium, optionally substituted deuterated-alkyl, or optionally substituted alkyl; or R c  and R d  taken together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring or optionally substituted deuterated-heterocyclic ring; or R c  and R d  taken together with the carbon atom to which they are attached form an optionally substituted carbocyclic ring or optionally substituted deuterated-carbocyclic ring; 
 with the proviso that the compound of Formula IV comprises at least one carbon-bound deuterium. 
 
       
     
     
         47 . The compound of  claim 46  having the structure of Formula II. 
     
     
         48 . The compound of  claim 47  having the structure of Formula IIB: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof. 
       
     
     
         49 . The compound of  claim 47 , having the following structure in deuterated form: 
       
         
           
           
               
               
           
         
       
     
     
         50 . The compound of  claim 46  having the structure of Formula IIIB. 
     
     
         51 . The compound of  claim 50 , wherein X is oxygen and R 24  is hydrogen. 
     
     
         52 . The compound of  claim 50  having the following structure in a deuterated form: 
       
         
           
           
               
               
           
         
       
     
     
         53 . The compound of  claim 50  selected from the group consisting of:
 deuterated-(2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; 
 deuterated-(2R,3R)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; 
 deuterated-(2R,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; 
 deuterated-(2S,3R)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; and 
 a mixture thereof; 
 
       or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof. 
     
     
         54 . A pharmaceutical composition comprising a compound of  claim 46 , or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof; and a pharmaceutically acceptable carrier. 
     
     
         55 . A method for treating a disorder involving degeneration or dysfunction of cells expressing p75 comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a compound of  claim 46  or a pharmaceutically acceptable salt, solvate, ester, or prodrug thereof. 
     
     
         56 . The method of  claim 55  wherein the disorder is a neurodegenerative disorder. 
     
     
         57 . The method of  claim 55  wherein the disorder is selected from the group consisting of Alzheimer's disease, Huntington's disease, Pick's disease, amyotrophic lateral sclerosis, epilepsy, Parkinson's disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation, multiple sclerosis, peripheral nerve injury, retinal degeneration, and hair loss. 
     
     
         58 . The method of  claim 57  wherein the disorder is selected from the group consisting of Alzheimer's disease, Huntington's disease, epilepsy, spinal cord injury, ischemia, brain injury, peripheral neuropathy, retinal degeneration, and hair loss.